<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">Presently, there is neither vaccine nor antiviral medication for human and zoological CoV 
 <xref rid="b0375" ref-type="bibr">[75]</xref>. The backbone management remains the induction of antiviral drugs as soon as possible following illness encounters. Nevertheless, prescription choices for SARS-CoV involved Ribavirin, a nucleoside analog with the significant drawback of lacking necessary in-vitro action against ECoV and with the significant side effect being hemolysis in several cases. Further, a boosted protease inhibitor regimen, lopinavir-ritonavir (LPV/r) have anti-CoV action in vitro, and IFN- alpha is a broad-spectrum antiviral medicine 
 <xref rid="b0185" ref-type="bibr">[37]</xref>. Similarly, there is no availability of precise or accredited MERS CoV human vaccines; besides, numerous CoV vaccines are at various developmental stages targeting both humans and dromedary camels 
 <xref rid="b0180" ref-type="bibr">[36]</xref>, 
 <xref rid="b0380" ref-type="bibr">[76]</xref>.
</p>
